CCD Research PLLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$10,000	1
2023	Research	$16,955	4
2022	Research	$114,657	13
2021	Research	$272,658	3
2020	Research	$19,924	1

Breakdown

Who paid Research payments · program years 2020–2025

Novartis Pharmaceuticals Corporation $276,605 4 payments
AbbVie, Inc. $87,447 11 payments
Eli Lilly and Company $60,142 6 payments
Takeda Pharmaceuticals U.S.A., Inc. $10,000 1 payment

Studies the money was for Research payments · program years 2020–2025

A Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 MG Over 32 Weeks in Adult Patients With Biopsy-Proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies - Prelude $276,605 4 payments
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy $79,947 10 payments
A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $36,157 2 payments
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $21,635 2 payments
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $10,000 1 payment
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab $7,500 1 payment
A Randomized Double-Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $1,500 1 payment
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $850 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.